A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00139854 |
Recruitment Status :
Completed
First Posted : August 31, 2005
Last Update Posted : August 30, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
ANXIETY | Drug: Alprazolam orally disintegrating tablets | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Official Title: | A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety |
Study Start Date : | August 2004 |
Actual Primary Completion Date : | November 2004 |
Actual Study Completion Date : | November 2004 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Currently being treated with conventional alprazolam
Exclusion Criteria:
- Dose of greater than 10 mg

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00139854
United States, Wisconsin | |
Schwarz | |
Milwaukee, Wisconsin, United States |
Study Director: | UCB Clinical Trial Call Center | UCB Pharma |
ClinicalTrials.gov Identifier: | NCT00139854 |
Other Study ID Numbers: |
SP829 |
First Posted: | August 31, 2005 Key Record Dates |
Last Update Posted: | August 30, 2013 |
Last Verified: | September 2009 |
Anxiety Disorders Mental Disorders Alprazolam Hypnotics and Sedatives Central Nervous System Depressants Physiological Effects of Drugs Anti-Anxiety Agents |
Tranquilizing Agents Psychotropic Drugs GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |